Biological Anti-IL-5/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis.

"Disclosure Dr Bryan Ross reports grants from QRHN, grants from MUHC-CAS, grants from MUHC-F, grants from Innovation & Partnership Grant (McGill & Thorasys), grants from MI-4 Grant, COPD Speakership (with speaker honorarium) from GSK, AstraZeneca, Covis, COPD Speakership (with speaker honorarium) and content developer from Canadian Thoracic Society, patient educational content developer from CHEST, Respiplus and AKA, COPD Speakership (with speaker honorarium) from APPQ, outside the submitted work. Dr Jean Bourbeau reports grants from Canadian Institute of Health Research (CIHR), grants from Quebec Respiratory Health Research Network (QRHN), grants from McGill University, grants from McGill University Health Centre Foundation, grants from Grifols, grants from Novartis, grants from Sanofi, personal fees from Pfizer Canada Ltd, personal fees from COVIS Pharma Canada Ltd, grants, personal fees from AstraZeneca Canada Ltd, grants, personal fees from Boehringer Ingelheim Canada Ltd, grants, personal fees from GlaxoSmithKline Canada Ltd, outside the submitted work. The authors report no other conflicts of interest in this work."

"Disclosure: Dr Bryan Ross reports grants from QRHN, grants from MUHC-CAS, grants from MUHC-F, grants from Innovation & Partnership Grant (McGill & Thorasys), grants from MI-4 Grant, COPD Speakership (with speaker honorarium) from GSK, AstraZeneca, Covis, COPD Speakership (with speaker honorarium) and content developer from Canadian Thoracic Society, patient educational content developer from CHEST, Respiplus and AKA, COPD Speakership (with speaker honorarium) from APPQ, outside the submitted work. Dr Jean Bourbeau reports grants from Canadian Institute of Health Research (CIHR), grants from Quebec Respiratory Health Research Network (QRHN), grants from McGill University, grants from McGill University Health Centre Foundation, grants from Grifols, grants from Novartis, grants from Sanofi, personal fees from Pfizer Canada Ltd, personal fees from COVIS Pharma Canada Ltd, grants, personal fees from AstraZeneca Canada Ltd, grants, personal fees from Boehringer Ingelheim Canada Ltd, grants, personal fees from GlaxoSmithKline Canada Ltd, outside the submitted work. The authors report no other conflicts of interest in this work."